Role of Genetic Susceptibility in the Development of Bronchopulmonary Dysplasia

Parad, Richard B.; Winston, Abigail B.; Kalish, Leslie A.; Gupta, Munish; Thompson, Ivana; Sheldon, Yvonne; Morey, JoAnn; Marter, Linda J. Van

doi:10.1016/j.jpeds.2018.07.099

Cited by 15 publications

(6 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…While their conclusion that the fetal environment plays a significant role in long‐term outcome was supported by our early biomarker findings, their proposition that genetic factors also contribute to respiratory outcomes has mixed support from the literature. Our own findings from twin pairs suggests that genetics does not significantly influence BPD risk in preterm neonates of this GA 28 …”

Section: Discussionmentioning

confidence: 68%

“…While their conclusion that the fetal environment plays a significant role in long-term outcome was supported by our early biomarker findings, their proposition that genetic factors also contribute to respiratory outcomes has mixed support from the literature. Our own findings from twin pairs suggests that genetics does not significantly influence BPD risk in preterm neonates of this GA. 28 Limitations of our 1-year trial include the small sample size and potential bias from loss to follow-up. There was no significant difference in the gestational age, birthweight, Apgar scores, or SNAPPE II scores between the 28 lost-to follow-up subjects and those on whom data were available for analysis.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Differences in clinical and laboratory biomarkers for short and long‐term respiratory outcomes in preterm neonates

Parad

Breeze

Terrin

et al. 2021

Pediatric Pulmonology

Self Cite

View full text Add to dashboard Cite

Background: Pulmonary outcome of premature neonates has focused more on short-term than long-term respiratory morbidities.Objective: Describe risk factors/biomarkers associated with short-term (bronchopulmonary dysplasia [BPD]) (supplemental oxygen use at 36 weeks postmenstrual age [PMA]) and longer-term (chronic respiratory morbidity [CRM]) (respiratory related symptoms, medications, medical/emergency visits, hospitalizations at 6-12 months corrected gestational age [CGA]) respiratory outcomes in a longitudinal cohort.Design/Methods: Neonates born at 24-29-week gestation were prospectively followed to 6-12-month CGA. Associations between clinical and laboratory risk factors/biomarkers of BPD and CRM were explored.Results: Of 86 subjects, 94% survived. Outcomes were available for 89% at 36-week PMA (BPD present in 42% of infants) and 72% at 6-12-month CGA (CRM present in 47% of infants). For the 54 infants with known outcomes for both BPD and CRM, diagnoses were discordant in 41%. BPD was associated with lower birthweight and birthweight Z-score for GA, lower Apgar scores, more surfactant doses, higher SNAPPE-II scores, highest Day 1 inspired oxygen concentration, Day 7 oxygen use, prolonged ventilatory support, bacteremia, necrotizing enterocolitis, and treated patent ductus arteriosus. CRM was associated with lower Apgar scores, Day 7 oxygen use and higher urine vascular endothelial growth factor. Patterns of plasma and urine lipid oxidation products differed in the two outcomes. Conclusion:In this hypothesis generating and exploratory study, BPD and CRM were associated with different risk factors/biomarker patterns. Concordance between these two outcomes was weak. Strategies for reducing CRM should be studied in cohorts identified by appropriate early risk factors/biomarkers.

show abstract

Section: Discussionmentioning

confidence: 68%

Section: Discussionmentioning

confidence: 99%

Differences in clinical and laboratory biomarkers for short and long‐term respiratory outcomes in preterm neonates

Parad

Breeze

Terrin

et al. 2021

Pediatric Pulmonology

Self Cite

View full text Add to dashboard Cite

show abstract

“…34 Genomic studies in BPD continue to work to identify heritable factors, with some studies arguing against the importance of heritable factors, although others argue that ongoing work will likely reveal important candidate genes. [35][36][37] Research on the maternal and neonatal microbiome holds promise, with a growing number of studies describing changes in the airway microbiome in infants with BPD. 38…”

Section: Antenatal Factors Associated With Development Of Bpdmentioning

confidence: 99%

Bronchopulmonary Dysplasia: Then, Now, and Next

Tracy

Cornfield

2020

Pediatric Allergy, Immunology, and Pulmonology

View full text Add to dashboard Cite

Bronchopulmonary dysplasia (BPD) has evolved considerably since its first description over 50 years ago. This review aims to provide a historical framework for conceptualizing BPD and a current understanding of the changing definition, epidemiology, pathophysiology, treatment, and outcomes of BPD. The transdisciplinary approach that led to the initial phenotypic description of BPD continues to hold promise today. Investigators are refining the definition of BPD in light of changes in clinical care and increasing survival rates of very preterm infants. Despite improvements in perinatal care the incidence of BPD continues to increase. There is growing recognition that antenatal risk factors play a key role in the development of BPD. Strategies designed to prevent or limit neonatal lung injury continue to evolve. Defining the phenotype of infants with BPD can meaningfully direct treatment. Infants with BPD benefit from an interdisciplinary approach to longitudinal care with a focus on growth and neurocognitive development. While the ultimate impact of BPD on long-term pulmonary morbidity remains an active area of investigation, current data indicate that most children and adolescents with a history of BPD have a quality of life comparable to that of other preterm infants.

show abstract

“…The clinical treatment of BPD has become a great challenge in perinatal and neonatal field. The pathogenesis of BPD is not clear at present, risk factors include preterm birth, fetal growth restriction, maternal smoking, mechanical ventilation, oxygen poisoning, infection, inflammation, patent ductus arteriosus (PDA), genetics, late surfactant deficiency, and impaired angiogenesis ( 5 – 13 ). Treatments for BPD include respiratory management, circulation management, nutritional support, and medication, including pulmonary surfactant, caffeine, glucocorticoid, diuretics, docosahexaenoic acid, and bronchodilator, however, the efficacy and safety need to be further explored ( 14 – 16 ).…”

Section: Introductionmentioning

confidence: 99%

Mesenchymal Stem Cell-Derived Extracellular Vesicles for the Treatment of Bronchopulmonary Dysplasia

Wang

2022

Front. Pediatr.

View full text Add to dashboard Cite

Bronchopulmonary dysplasia (BPD) is the most common chronic respiratory disease in premature infants. However, there is a lack of effective treatment. Mesenchymal stromal cells derived extracellular vesicles (MSC-EVs), as nano- and micron-sized heterogeneous vesicles secreted by MSCs, are the main medium for information exchange between MSCs and injured tissue and organ, playing an important role in repairing tissue and organ injury. EVs include exosomes, microvesicles and so on. They are rich with various proteins, nucleic acids, and lipids. Now, EVs are considered as a new way of cell-to-cell communication. EVs mainly induce regeneration and therapeutic effects in different tissues and organs through the biomolecules they carry. The surface membrane protein or loaded protein and nucleic acid molecules carried by EVs, can activate the signal transduction of target cells and regulate the biological behavior of target cells after binding and cell internalization. MSC-EVs can promote the development of pulmonary vessels and alveoli and reduce pulmonary hypertension (PH) and inflammation and play an important role in the repair of lung injury in BPD. The regeneration potential of MSC-EVs is mainly due to the regulation of cell proliferation, survival, migration, differentiation, angiogenesis, immunoregulation, anti-inflammatory, mitochondrial activity and oxidative stress. As a new type of cell-free therapy, MSC-EVs have non-immunogenic, and are small in size and go deep into most tissues. What’s more, it has good biological stability and can be modified and loaded with drugs of interest. Obviously, MSC-EVs have a good application prospect in the treatment of lung injury and BPD. However, there are still many challenges to make MSC-EVs really enter clinical application.

show abstract

Role of Genetic Susceptibility in the Development of Bronchopulmonary Dysplasia

Cited by 15 publications

References 27 publications

Differences in clinical and laboratory biomarkers for short and long‐term respiratory outcomes in preterm neonates

Differences in clinical and laboratory biomarkers for short and long‐term respiratory outcomes in preterm neonates

Bronchopulmonary Dysplasia: Then, Now, and Next

Mesenchymal Stem Cell-Derived Extracellular Vesicles for the Treatment of Bronchopulmonary Dysplasia

Contact Info

Product

Resources

About